rapid diagnostic test

Use of a highly-sensitive rapid diagnostic test to screen for malaria in pregnancy in Indonesia

Tags:

rapid diagnostic test, malaria, pregnancy, Indonesia

Author(s):

Vera T. Unwin, Rukhsana Ahmed, Emily R. Adams, et al.

Reference:

Malaria Journal 2020 19:28, 16 January 2020

The sensitivity of rapid diagnostic tests (RDTs) for malaria is inadequate for detecting low-density, often asymptomatic infections, such as those that can occur when screening pregnant women for malaria. The performance of the Alere™ Ultra-sensitive Malaria Ag Plasmodium falciparum RDT (uRDT) was assessed retrospectively in pregnant women in Indonesia.

Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis

Tags:

Access Bio/CareStart, rapid diagnostic test, glucose-6-phosphate dehydrogenase

Author(s):

Ley B, Winasti Satyagraha A, Price RN, et al.

Reference:

PLoS Med. 2019 Dec 13; 16(12):e1002992.

To reduce the risk of drug-induced haemolysis, all patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine (PQ)-based radical cure for the treatment of vivax malaria. This systematic review and individual patient meta-analysis assessed the utility of a qualitative lateral flow assay from Access Bio/CareStart (Somerset, NJ) (CareStart Screening test for G6PD deficiency) for the diagnosis of G6PDd compared to the gold standard spectrophotometry (International Prospective Register of Systematic Reviews [PROSPERO]: CRD42019110994).

A review of the WHO malaria rapid diagnostic test product testing programme (2008–2018): performance, procurement and policy

Tags:

rapid diagnostic test, product testing

Author(s):

Jane Cunningham, Sophie Jones, Michelle L. Gatton, John W. Barnwell, Qin Cheng, Peter L. Chiodini, Jeffrey Glenn, Sandra Incardona, Cara Kosack, Jennifer Luchavez, Didier Menard, Sina Nhem, Wellington Oyibo, Roxanne R. Rees-Channer, Iveth Gonzalez and David Bell

Reference:

Malaria Journal 2019 18:387, 2 December 2019

Malaria rapid diagnostic tests (RDTs) emerged in the early 1990s into largely unregulated markets, and uncertain field performance was a major concern for the acceptance of tests for malaria case management. This, combined with the need to guide procurement decisions of UN agencies and WHO Member States, led to the creation of an independent, internationally coordinated RDT evaluation programme aiming to provide comparative performance data of commercially available RDTs.

Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania

Tags:

glucose-6-phosphate dehydrogenase activity, CareStart G6PD, rapid diagnostic test, associated genetic variants, endemic setting

Author(s):

Oum kelthoum Mamadou Djigo, Mohamed Abdallahi Bollahi, Moina Hasni Ebou, Mohamed Salem Ould Ahmedou Salem, Rachida Tahar, Hervé Bogreau, Leonardo Basco, Ali Ould Mohamed Salem Boukhary

Reference:

PLoS ONE 14(9): e0220977

Primaquine is recommended by the World Health Organization (WHO) for radical treatment of Plasmodium vivax malaria. This drug is known to provoke acute hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Due to lack of data on G6PD deficiency, the use of primaquine has been limited in Africa. In the present study, G6PD deficiency was investigated in blood donors of various ethnic groups living in Nouakchott, a P. vivax endemic area in Mauritania.

Organization:

World Health Organization (WHO)

Country:

Mauritania

Medical Condition:

Plasmodium vivax malaria

Search form

You are here